arGentis Receives Favorable Opinion for European Orphan Drug Designation.
Business Wire › January 06, 2009
Linked as:
Extract
arGentis Receives Favorable Opinion for European Orphan Drug Designation.
MEMPHIS, Tenn. -- arGentis Pharmaceuticals, LLC announced today that the European Medicines Agency's (EMEA) Committee for Orphan Medicinal Products (COMP) adopted a positive opinion recommending the company's product candidate ARG201 (native type 1 bovine collagen) f...
See the full content of this document
Sponsored links
